Eosinophil response in mast cell-deficient W/WV mice.
The combination of cyclophosphamide treatment and Toxocara canis infection is known as an effective way of causing a high level of eosinophilia in mice. When this treatment was applied to congenitally anemic, mast cell-deficient W/WV mice, eosinophil response was far less than that of their normal littermate +/+ mice. The degree of the defective eosinophil response in the peripheral blood of W/WV mice was severer than that in the bone marrow. The defective eosinophil response of W/WV mice was completely restored by bone marrow grafting 8 weeks prior to cyclophosphamide treatment and T. canis infection. The kinetics of the recovery of eosinophil response in the bone marrow of W/WV mice after bone marrow grafting was faster than that in the peripheral blood. Chemotactic reactivity of eosinophils obtained from bone marrow or peritoneal cavity of W/WV mice was essentially comparable to that of +/+ mice. These results suggest that, in addition to the production of eosinophils in the bone marrow, mast cell-derived factors play an important role in the mediation of peripheral blood eosinophilia.
D000818:Animals; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D002454:Cell Differentiation / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004802:Eosinophilia / Q000139:chemically induced; D004804:Eosinophils / Q000187:drug effects / Q000502:physiology*; D005260:Female; D007700:Kinetics; D007958:Leukocyte Count; D008407:Mast Cells / Q000502:physiology*; D051379:Mice; D008815:Mice, Inbred Strains / Q000097:blood / Q000235:genetics; D010529:Peritoneal Cavity / Q000166:cytology; D013997:Time Factors; D014120:Toxocariasis / Q000097:blood / Q000503:physiopathology
D003520:Cyclophosphamide